QuickView for TFS-II;jsessionid=FD9D07EA4FEA2E9D62FC365AA7DE59D3;jsessionid=9A293F9B4FD554D3CFAA1B9898B171E8;jsessionid=C8B5755C1AB667BEC9CC28337B057DA7;jsessionid=C1A62CE3455E97C87B6E5FC8388D846F;jsessionid=4BCCC9F0EC33103311475DC571D6E95B;jsessionid=099EB1E6DD2B60FF7E32E0C725092659;jsessionid=60217AF0C6214DB8FA2C55CF84DC211F;jsessionid=7267B70EEEDAE9086F0646E1AF3CD22F;jsessionid=C1AD908B100685E8A6F24CE9FBE22279;jsessionid=140A75D41915CE70D4BE5B47FBFC3763;jsessionid=8065DA9CDE976E87CF43AFB6853A5E8E (gene)

1. Thymic stroma and TFII-I: towards new targeted therapies.
2. Proteomic analysis of SRF associated transcription complexes identified TFII-I as modulator of SRF f…
3. Structural basis for evolutionarily conserved interactions between TFIIS and Paf1C.
4. The TFIIS N-terminal domain (TND): a transcription assembly module at the interface of order and dis…
5. Astragaloside IV attenuates sunitinib-associated cardiotoxicity by inhibiting COUP-TFII.

There were no clinical trials for TFS-II;jsessionid=FD9D07EA4FEA2E9D62FC365AA7DE59D3;jsessionid=9A293F9B4FD554D3CFAA1B9898B171E8;jsessionid=C8B5755C1AB667BEC9CC28337B057DA7;jsessionid=C1A62CE3455E97C87B6E5FC8388D846F;jsessionid=4BCCC9F0EC33103311475DC571D6E95B;jsessionid=099EB1E6DD2B60FF7E32E0C725092659;jsessionid=60217AF0C6214DB8FA2C55CF84DC211F;jsessionid=7267B70EEEDAE9086F0646E1AF3CD22F;jsessionid=C1AD908B100685E8A6F24CE9FBE22279;jsessionid=140A75D41915CE70D4BE5B47FBFC3763;jsessionid=8065DA9CDE976E87CF43AFB6853A5E8E